semaglutide fda approval mash Novo's Wegovy becomes first GLP-1 drug approved for FDA Approval of Semaglutide for

Despite no longer being a general exclusion, an insurance provider may not include Ozempic or Wegovy on their prescription drug plan formulary

A 2019 study published in Diabetes Care (Frias et al.) examined the combination of semaglutide with an SGLT2 inhibitor and found additive reductions in both HbA1c and body weight compared to either medication used alone, with no significant increase in adverse events beyond what was expected from each medication individually

Regardless of your opinions of compounding GLP-1s and the durability of the business, those are impressive results

Online sellers are operating outside MHRA oversight

95% CI: 0.0180.049

Clinical studies show that patients typically lose 10-20% of their body weight over several months with GLP-1 therapy